BioCentury | Mar 6, 2021
Emerging Company Profile

Proxygen’s knockout take on targeted protein degradation

Austrian newco Proxygen is identifying cancer therapies that act via protein degradation by screening candidates in cells that can’t send proteins to the trash. Founded last May, Proxygen GmbH has raised seed funding from the Austrian government...
BioCentury | Mar 6, 2021
Emerging Company Profile

Araris: universal linkers for antibody-drug conjugates

Araris is developing antibody-drug conjugate linker technology that could widen the therapeutic window for ADCs by improving their stability and solubility. In addition, the Swiss biotech’s peptide linkers...
BioCentury | Mar 3, 2021
Product Development

NIH halts COVID-19 convalescent plasma trial, renewing calls for FDA to withdraw authorization

NIH announced Tuesday that it has halted a trial of COVID-19 convalescent plasma to treat emergency department patients who developed mild-to-moderate symptoms of COVID-19 because there was no evidence of efficacy. The move renewed calls...
BioCentury | Mar 2, 2021
Politics, Policy & Law

Whither Woodcock; plus refresh for German biotech & modalities to market: a BioCentury podcast

Opposition by a handful of Democratic senators could scuttle Janet Woodcock’s chances to be nominated as permanent FDA commissioner, even as she has broad support among patient groups, clinicians and biopharma...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...
BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

NK cell therapy company Artiva Biotherapeutics Inc. raised $120 million in a series B financing led by Venrock Healthcare Capital Partners. Other new investors participating included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton,...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

After its $135 million series C raise Wednesday, Vividion has everything in place to take advantage of the surging market for IPOs: a broad syndicate of crossover investors, pharma partners in BMS and Roche, a CEO...
BioCentury | Feb 24, 2021
Product Development

Insilico’s IPF candidate links, and tests, AI-led target and compound discovery

Developed in less than 18 months for $1.8 million, Insilico’s preclinical lung fibrosis candidate showcases the speed and cost advantages of marrying the AI company’s target and compound discovery platforms. The question is whether linking...
BioCentury | Feb 23, 2021
Distillery Therapeutics

CRISPR-Cas13a targeting of viral genes for COVID-19, flu

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus; influenza CRISPR-Cas13a knockdown of the nucleocapsid protein of SARS-CoV-2 or influenza’s viral RNA polymerase could treat COVID-19 or flu, respectively. In monkey kidney cells infected with SARS-CoV-2, Cas13a targeting of the...
Items per page:
1 - 10 of 6399
BioCentury | Mar 6, 2021
Emerging Company Profile

Proxygen’s knockout take on targeted protein degradation

Austrian newco Proxygen is identifying cancer therapies that act via protein degradation by screening candidates in cells that can’t send proteins to the trash. Founded last May, Proxygen GmbH has raised seed funding from the Austrian government...
BioCentury | Mar 6, 2021
Emerging Company Profile

Araris: universal linkers for antibody-drug conjugates

Araris is developing antibody-drug conjugate linker technology that could widen the therapeutic window for ADCs by improving their stability and solubility. In addition, the Swiss biotech’s peptide linkers...
BioCentury | Mar 3, 2021
Product Development

NIH halts COVID-19 convalescent plasma trial, renewing calls for FDA to withdraw authorization

NIH announced Tuesday that it has halted a trial of COVID-19 convalescent plasma to treat emergency department patients who developed mild-to-moderate symptoms of COVID-19 because there was no evidence of efficacy. The move renewed calls...
BioCentury | Mar 2, 2021
Politics, Policy & Law

Whither Woodcock; plus refresh for German biotech & modalities to market: a BioCentury podcast

Opposition by a handful of Democratic senators could scuttle Janet Woodcock’s chances to be nominated as permanent FDA commissioner, even as she has broad support among patient groups, clinicians and biopharma...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...
BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

NK cell therapy company Artiva Biotherapeutics Inc. raised $120 million in a series B financing led by Venrock Healthcare Capital Partners. Other new investors participating included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton,...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

After its $135 million series C raise Wednesday, Vividion has everything in place to take advantage of the surging market for IPOs: a broad syndicate of crossover investors, pharma partners in BMS and Roche, a CEO...
BioCentury | Feb 24, 2021
Product Development

Insilico’s IPF candidate links, and tests, AI-led target and compound discovery

Developed in less than 18 months for $1.8 million, Insilico’s preclinical lung fibrosis candidate showcases the speed and cost advantages of marrying the AI company’s target and compound discovery platforms. The question is whether linking...
BioCentury | Feb 23, 2021
Distillery Therapeutics

CRISPR-Cas13a targeting of viral genes for COVID-19, flu

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus; influenza CRISPR-Cas13a knockdown of the nucleocapsid protein of SARS-CoV-2 or influenza’s viral RNA polymerase could treat COVID-19 or flu, respectively. In monkey kidney cells infected with SARS-CoV-2, Cas13a targeting of the...
Items per page:
1 - 10 of 6399